CY1112590T1 - 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ - Google Patents

3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ

Info

Publication number
CY1112590T1
CY1112590T1 CY20121100315T CY121100315T CY1112590T1 CY 1112590 T1 CY1112590 T1 CY 1112590T1 CY 20121100315 T CY20121100315 T CY 20121100315T CY 121100315 T CY121100315 T CY 121100315T CY 1112590 T1 CY1112590 T1 CY 1112590T1
Authority
CY
Cyprus
Prior art keywords
divenzo
oxazepin
bimetal
piperazin
treatment
Prior art date
Application number
CY20121100315T
Other languages
Greek (el)
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion, Inc. filed Critical Hypnion, Inc.
Publication of CY1112590T1 publication Critical patent/CY1112590T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20[b, f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20121100315T 2004-09-21 2012-03-28 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ CY1112590T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
EP05801120A EP1804804B1 (en) 2004-09-21 2005-09-21 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number Publication Date
CY1112590T1 true CY1112590T1 (el) 2016-02-10

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100315T CY1112590T1 (el) 2004-09-21 2012-03-28 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ

Country Status (19)

Country Link
US (3) US7592333B2 (enExample)
EP (1) EP1804804B1 (enExample)
JP (1) JP5049129B2 (enExample)
KR (1) KR101264444B1 (enExample)
AT (1) ATE542536T1 (enExample)
AU (1) AU2005286713B2 (enExample)
BR (1) BRPI0515518A (enExample)
CA (1) CA2580250C (enExample)
CY (1) CY1112590T1 (enExample)
DK (1) DK1804804T3 (enExample)
EA (1) EA012610B1 (enExample)
ES (1) ES2378452T3 (enExample)
MA (1) MA28985B1 (enExample)
MX (1) MX2007003032A (enExample)
NO (1) NO20071604L (enExample)
NZ (1) NZ553900A (enExample)
PL (1) PL1804804T3 (enExample)
PT (1) PT1804804E (enExample)
WO (1) WO2006034414A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
WO2006049734A2 (en) * 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
RU2459811C2 (ru) * 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
BRPI0808828A8 (pt) * 2007-03-15 2017-11-28 Aryx Therapeutics Inc Compostos de dibenzo[b,f][1,4]oxazapina
US8827979B2 (en) 2007-03-19 2014-09-09 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CN102245137A (zh) 2008-11-07 2011-11-16 茵苏莱恩医药有限公司 用于药物递送的装置和方法
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
AU2020370063B2 (en) * 2019-10-21 2025-10-23 Alairion, Inc. 3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propanoic acid derivatives as H1 and 5-HT2A-receptor modulators for the treatment of sleep disorders
WO2025076527A1 (en) * 2023-10-07 2025-04-10 Inspire Medical Systems, Inc. Pulmonary therapy for sleep disordered breathing care

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (enExample) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20050049146A1 (en) 2001-11-05 2005-03-03 Chiarello John F. Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
MX2007003032A (es) 2007-05-21
MA28985B1 (fr) 2007-11-01
US7592333B2 (en) 2009-09-22
NZ553900A (en) 2010-10-29
EP1804804B1 (en) 2012-01-25
WO2006034414A2 (en) 2006-03-30
EA200700702A1 (ru) 2007-10-26
PT1804804E (pt) 2012-03-30
US20090186872A1 (en) 2009-07-23
WO2006034414A3 (en) 2006-09-08
JP5049129B2 (ja) 2012-10-17
NO20071604L (no) 2007-06-20
EA012610B1 (ru) 2009-10-30
PL1804804T3 (pl) 2012-08-31
AU2005286713A1 (en) 2006-03-30
EP1804804A2 (en) 2007-07-11
AU2005286713B2 (en) 2010-10-28
CA2580250A1 (en) 2006-03-30
DK1804804T3 (da) 2012-02-20
KR101264444B1 (ko) 2013-05-20
EP1804804A4 (en) 2010-11-24
CA2580250C (en) 2013-05-14
US20060063928A1 (en) 2006-03-23
ES2378452T3 (es) 2012-04-12
US8101596B2 (en) 2012-01-24
US20060063755A1 (en) 2006-03-23
KR20070060126A (ko) 2007-06-12
BRPI0515518A (pt) 2008-07-29
ATE542536T1 (de) 2012-02-15
JP2008513510A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
CY1112590T1 (el) 3-[4-(ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝ-11-ΥΛΟ)-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ]-2,2-ΔΙΜΕΘΥΛΟ ΠΡΟΠΑΝΟΪΚΟ ΟΞΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΙΑΤΑΡΑΧΩΝ ΤΟΥ ΥΠΝΟΥ
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
ATE517896T1 (de) P38-kinase-inhibitoren
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
EA201000145A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
ZA200701137B (en) Triazolophthalazines
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE428417T1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
ATE445402T1 (de) Neue verwendung von pde5-hemmern
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE531703T1 (de) Benzochromenderivate
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
DE602005027866D1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren
ATE437846T1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe